Search results for "Lipids"

showing 10 items of 2228 documents

Involvement of prostaglandins and 5-hydroxytryptamine in the contractile effect of platelet-activating factor in rat isolated gastric corpus

1996

Abstract The present study characterizes the nature of the response to the platelet-activating factor (PAF) in isolated gastric corpus with and without mucosa. PAF (10-8 M) induced contraction of rat isolated gastric corpus strips followed by desensitization of this tissue. Incubation of strips with the specific PAF-receptor antagonist WEB 2086 (5 × 10-8 − 5 × 10-5 M), the prostaglandin blocker indomethacin (10-6 M) and the 5-hydroxytryptamine antagonist methysergide (10-5 M) reduced significantly the contraction induced by PAF. Neither of the histamine H1/H2 antagonists diphenhydramine (10-6 M) or cimetidine (10-5 M) affected the contraction induced by PAF. In contrast with the whole gastr…

Malemedicine.medical_specialtySerotoninContraction (grammar)Prostaglandin AntagonistsMethysergidePharmaceutical ScienceProstaglandinBiologyIn Vitro Techniqueschemistry.chemical_compoundInternal medicinemedicineGastric mucosaAnimalsCimetidinePlatelet Activating FactorRats WistarPharmacologyPlatelet-activating factorStomachAntagonistMuscle Smoothrespiratory systemAcetylcholineRatsEndocrinologymedicine.anatomical_structurechemistryHistamine H2 AntagonistsGastric MucosaHistamine H1 AntagonistsProstaglandinsFemalelipids (amino acids peptides and proteins)Serotonin Antagonistsmedicine.symptomGastrointestinal MotilityMuscle contractionmedicine.drugMuscle Contraction
researchProduct

Involvement of secretory phospholipase A2 activity in the zymosan rat air pouch model of inflammation.

1996

1. In the zymosan rat air pouch model of inflammation we have assessed the time dependence of phospholipase A2 (PLA2) accumulation in the inflammatory exudates as well as cell migration, myeloperoxidase activity, prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) levels. 2. A significant increase in PLA2 activity was detected in 1,200 g supernatants of exudates 8 h after injection of zymosan into rat air pouch. This event coincided with peaks in cell accumulation (mainly neutrophils) and myeloperoxidase activity in exudates and was preceded by a rise in eicosanoid levels. 3. This enzyme (without further purification) behaved as a secretory type II PLA2 with an optimum pH at 7-8 units, lack o…

Malemedicine.medical_specialtySesterterpenesLeukotriene B4NeutrophilsAnti-Inflammatory AgentsLeukotriene B4DinoprostonePhospholipases AManoalidechemistry.chemical_compoundPhospholipase A2Internal medicinemedicineAnimalsProstaglandin E2Rats WistarPeroxidasePharmacologyInflammationAnalysis of VariancebiologyTerpenesZymosanZymosanRatsPhospholipases A2EndocrinologyEicosanoidBiochemistrychemistryMyeloperoxidasebiology.proteinHomosteroidslipids (amino acids peptides and proteins)PouchColchicinemedicine.drugResearch ArticleBritish journal of pharmacology
researchProduct

Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercho…

2013

Hypercholesterolemic patients (n = 1,547) at high atherosclerotic cardiovascular disease risk with low-density lipoprotein cholesterol (LDL-C) levels ≥100 and ≤160 mg/dl while treated with atorvastatin 10 mg/day entered a multicenter, randomized, double-blind, active-controlled, clinical trial using two 6-week study periods. Period I compared the efficacy/safety of (1) adding ezetimibe 10 mg (ezetimibe) to stable atorvastatin 10 mg, (2) doubling atorvastatin to 20 mg, or (3) switching to rosuvastatin 10 mg. Subjects in the latter 2 groups who persisted with elevated LDL-C levels (≥100 and ≤160 mg/dl) after period I, entered period II; subjects on atorvastatin 20 mg had ezetimibe added to th…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaAtorvastatinHypercholesterolemiaUrologylaw.inventionchemistry.chemical_compoundEzetimibeRandomized controlled trialDouble-Blind Methodlawhealth services administrationInternal medicineprimary hypercholesterolemiaatorvastatin; ezetimibe; rosuvastatin; primary hypercholesterolemiamedicineAtorvastatinHumansRosuvastatinIn patientPyrrolescardiovascular diseasesRosuvastatin CalciumAgedSulfonamidesCholesterolbusiness.industryAnticholesteremic Agentsnutritional and metabolic diseasesCholesterol LDLMiddle AgedEzetimibeClinical trialFluorobenzenesRosuvastatin CalciumLogistic ModelsPyrimidineschemistryHeptanoic AcidsCardiologyAzetidineslipids (amino acids peptides and proteins)Drug Therapy CombinationFemaleCardiology and Cardiovascular Medicinebusinessrosuvastatinmedicine.drugThe American journal of cardiology
researchProduct

Hypertension and diabetes mellitus are associated with cardiovascular events in the elderly without cardiovascular disease. Results of a 15-year foll…

2009

Abstract Background and aims Epidemiological prospective data on cardiovascular (CV) events in elderly subjects from Mediterranean populations are lacking. We aimed to investigate 15-year incidence of CV events and to evaluate the association with CV risk factors in an elderly Mediterranean population. Methods and results The population of a small Sicilian village were enrolled, visited and a blood sample was drawn at baseline. CV events were recorded in the 15 years of follow-up. From 1351 subjects (75% of the resident population); 315 were in the age range 65–85 years; 266 subjects free from CV disease were analysed. Seventy-seven CV events were recorded in 73 out of 266 subjects, with a …

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaEpidemiologyEndocrinology Diabetes and MetabolismPopulationPrevalenceMedicine (miscellaneous)Prospective dataDiseaseDiabetes ComplicationsElderlyRisk FactorsInternal medicineDiabetes mellitusEpidemiologymedicineHumansStatistical analysiseducationAgedAged 80 and overInflammationeducation.field_of_studyNutrition and Dieteticsdiabetesbusiness.industryIncidence (epidemiology)Incidencemedicine.diseaseCardiovascular diseaseLipidsSurvival AnalysisDiabetes Mellitus Type 2ItalyCardiovascular DiseasesHypertensionPhysical therapyFemaleRisk factorCardiology and Cardiovascular MedicinebusinessFollow-Up Studies
researchProduct

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

2015

BACKGROUND: Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy. Larger and longer-term studies are needed to establish safety and efficacy.METHODS: We conducted a randomized trial involving 2341 patients at high risk for cardiovascular events who had LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or more and were receiving treatment with statins at the maximum tolerated dose (the highest dose associated with an acceptable side-effect profile), with or without other lipid-lowering therapy. Patients were …

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaIntention to Treat AnalysiHypercholesterolemiaUrologyalirocumabBococizumabPharmacologyPlaceboAged; Antibodies Monoclonal; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Drug Therapy Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intention to Treat Analysis; Male; Middle Aged; Medicine (all)law.inventionchemistry.chemical_compoundcardiovascular eventsDouble-Blind MethodRandomized controlled triallawCardiovascular DiseaseAnticholesteremic AgentMedicineproprotein convertase subtilisin–kexin type 9 (PCSK9)High Cardiovascular Risk PatientsAgedAlirocumabalirocumab; cholesterol; cardiovascular eventsCholesterolbusiness.industryMedicine (all)PCSK9Antibodies MonoclonalcholesterolCholesterol LDLGeneral MedicineMiddle AgedLomitapideEvolocumabchemistrylow-density lipoprotein (LDL) cholesterol[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase Inhibitorbusiness[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyHumanNew England journal of medicine
researchProduct

The relationships between lipid ratios and arterial stiffness

2017

Although dyslipidemia is associated with cardiovascular disease, there are conflicting data about the role of serum lipids and their ratios in promoting arterial stiffness. The authors aimed to compare serum lipid profiles to predict arterial stiffness, which was assessed by brachial‐ankle pulse wave velocity in young Chinese men. A total of 1015 participants aged 18 to 44 years without serious comorbidities were recruited for conventional detection. Anthropometrics, brachial‐ankle pulse wave velocity, serum lipids, and other laboratory data were measured. Univariate analysis and multivariate logistic regression were performed to examine the relationship between serum lipid profiles and bra…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaLipoproteinsEndocrinology Diabetes and Metabolism030204 cardiovascular system & hematology03 medical and health sciencesVascular Stiffness0302 clinical medicineInternal medicineInternal MedicineHumansMedicine030212 general & internal medicineARTERIOSCLEROSIS - ARTERIAL STIFFNESS - LIPIDS - HYPERTENSIONSettore MED/14 - Nefrologiabusiness.industrynutritional and metabolic diseasesmedicine.diseaseLipidsSettore MED/11 - Malattie Dell'Apparato CardiovascolareSurgeryHypertensionArterial stiffnessCardiologyArterial Stiffnesslipids (amino acids peptides and proteins)Cardiology and Cardiovascular Medicinebusiness
researchProduct

Decreased plasma soluble RAGE in patients with hypercholesterolemia: Effects of statins

2007

The receptor for advanced glycation endproducts (RAGE) is overexpressed at sites of vascular pathology. A soluble RAGE isoform (sRAGE) neutralizes the ligand-mediated damage by acting as a decoy. We hypothesized that in hypercholesterolemia up-regulation of the ligand-RAGE axis may bridge impairment of nitric oxide biosynthesis with oxidative stress. We measured in 60 hypercholesterolemic patients and 20 controls plasma total sRAGE levels, urinary 8-iso-prostaglandin (PG) F(2alpha) excretion, and plasma levels of asymmetric dimethylarginine (ADMA). The effects of two structurally different statins (pravastatin and atorvastatin) on these parameters were analyzed in 20 hypercholesterolemic su…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaStatinmedicine.drug_classAtorvastatinHypercholesterolemiaReceptor for Advanced Glycation End ProductsFree radicalsArginineDinoprostNitric Oxidemedicine.disease_causeBiochemistrychemistry.chemical_compoundDouble-Blind MethodPhysiology (medical)Internal medicineHyperlipidemiaAtorvastatinmedicineHumansPyrrolesReceptors ImmunologicEndothelial dysfunctionPravastatinChemistryVascular diseaseAnticholesteremic AgentsStatinnutritional and metabolic diseasesMiddle AgedAtherosclerosismedicine.diseaseADMACross-Sectional StudiesHyperlipidemiaEndocrinologyHeptanoic AcidsOxidative streFemalelipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsNitric Oxide SynthaseAsymmetric dimethylarginineOxidative stressPravastatinsRAGEmedicine.drugFree Radical Biology and Medicine
researchProduct

Effects of fluvastatin slow-release (XL 80 mg) versus simvastatin (20 mg) on the lipid triad in patients with type 2 diabetes.

2005

The lipid triad is the association of small, dense (sd) low-density lipoprotein (LDL), low high-density lipoprotein (HDL), and hypertriglyceridemia, all of which play a role in coronary artery disease in patients with type 2 diabetes. Although statins have demonstrated clear positive effects on cardiovascular morbidity/mortality in patients with diabetes and on single components of the lipid triad, it remains controversial whether they affect all components of the triad in these patients. Therefore, we performed a single-center, parallel-group, prospective, randomized, open-label, blinded-endpoint (PROBE)-type comparison of fluvastatin extended-release (XL) 80 mg (n=48) and simvastatin 20 m…

Malemedicine.medical_specialtySimvastatinIndolesHDLApolipoprotein BSmall dense LDLType 2 diabetesTriglycerideLDLFatty Acids MonounsaturatedFluvastatin XLInternal medicineDiabetes mellitusType 2 diabetes mellitusmedicineHumansPharmacology (medical)Prospective StudiesFluvastatinAgedHypertriglyceridemiabiologybusiness.industryAnticholesteremic AgentsApoA-IHypertriglyceridemianutritional and metabolic diseasesType 2 Diabetes MellitusGeneral MedicineMiddle Agedmedicine.diseaseLipoproteins LDLEndocrinologyDiabetes Mellitus Type 2SimvastatinDelayed-Action Preparationsbiology.proteinlipids (amino acids peptides and proteins)FemaleApoBbusinessLipoproteins HDLFluvastatinmedicine.drugLipoproteinAdvances in therapy
researchProduct

Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and …

2009

Abstract Background Effects independent from cholesterol reduction on vascular function are considered to importantly contribute to the beneficial effects of statin therapy in cardiovascular disease. We aimed to evaluate the effect of high versus low dose atorvastatin on endothelial dysfunction in patients with coronary artery disease (CAD) in a setting of comparable cholesterol reduction. Methods and results Fifty-eight patients with CAD were randomly assigned to double-blind treatment for 8 weeks with atorvastatin 80mg per day (A80) or atorvastatin 10mg+ezetimibe 10mg per day (A10E10), respectively. Flow-mediated vasodilation (FMD) of the brachial artery, nitroglycerin-mediated endotheliu…

Malemedicine.medical_specialtyStatinmedicine.drug_classAtorvastatinCoronary Artery DiseaseCoronary artery diseasechemistry.chemical_compoundEzetimibeDouble-Blind Methodmedicine.arteryInternal medicinemedicineAtorvastatinHumansPyrrolescardiovascular diseasesEndothelial dysfunctionBrachial arteryAgedbiologybusiness.industryCholesterolAnticholesteremic AgentsCholesterol LDLMiddle Agedmedicine.diseaseAtherosclerosisEzetimibeEndocrinologyC-Reactive ProteinCholesterolTreatment OutcomechemistryHeptanoic AcidsHMG-CoA reductaseCardiologybiology.proteinAzetidineslipids (amino acids peptides and proteins)FemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugAtherosclerosis
researchProduct

Should low high-density lipoprotein cholesterol (HDL-C) be treated?

2014

The first observations linking a low serum level of HDL-C to increased risk for cardiovascular disease were made over 50 years ago. High serum levels of HDL-C appear to protect against the development of atherosclerotic disease, while low serum levels of this lipoprotein are among the most important predictors of atherosclerotic disease in both men and women and people of all racial and ethnic groups throughout the world. It has long been assumed that therapeutic interventions targeted at raising HDL-C levels would lower risk for such cardiovascular events as myocardial infarction, ischemic stroke, and death. Even after five decades of intensive investigation, evidence to support this assum…

Malemedicine.medical_specialtyStatinmedicine.drug_classEndocrinology Diabetes and MetabolismDiseaseLower riskNiacinlaw.inventionCoronary artery diseaseEndocrinologyRandomized controlled triallawRisk FactorsInternal medicinemedicineHumansMyocardial infarctionDyslipidemiasbusiness.industryReverse cholesterol transportCholesterol HDLFibric Acidsmedicine.diseaseEndocrinologyCardiovascular Diseaseslipids (amino acids peptides and proteins)FemaleThiazolidinedionesHydroxymethylglutaryl-CoA Reductase Inhibitorsbusinesscoronary artery disease fibrate high-density lipoproteins low-density lipoproteins niacin reverse cholesterol transport statin thiazolidinedioneNiacin
researchProduct